Understanding the pathophysiology of multiple sclerosis and the development of new therapies

touchTALKS for touchIMMUNOLOGY

Listen to a leading expert in the management of patients with multiple sclerosis review the cellular model of disease, and how disease pathophysiology can offer novel therapeutic targets. Prof. Derfuss outlines the role of immune cells in driving multiple sclerosis pathogenesis, explains how the pathobiology of the disease has driven the development of disease-modifying therapies, and reviews the mechanism of action and clinical trial landscape for Bruton’s tyrosine kinase inhibitors.

The expert

• Prof. Tobias Derfuss, University Hospital Basel, Switzerland

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany.  This activity is jointly provided by USF Health and touchIME.

For further information visit our website https://touchimmunologyime.org/pathophysiology_of_ms_and_development_of_treatments/